Home・Akciju saraksts・OPKO Health Inc

OPKO Health Inc

Slēgts

SektorsVeselības aprūpe

1.39 1.46

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.35

Max

1.3900000000000001

Galvenie mērījumi
By Trading Economics
Ienākumi	46M -8.4M
Pārdošana	39M 164M
EPS	-0.01
Peļņas marža	-5.145
Darbinieki	2,275
EBITDA	40M 12M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+115.83% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 28. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	72M 978M
Iepriekšējā atvēršanas cena	-0.07
Iepriekšējā slēgšanas cena	1.39

Ziņu noskaņojums

By Acuity

67%

33%

286 / 340 Rangs Healthcare

OPKO Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. aug. 19:46 UTC

OPKO Health Inc. shares are trading higher amid broader market uncertainty, reflecting notable strength above its 20-day moving average since Friday's close.

2026. g. 7. aug. 23:01 UTC

OPKO Health shares advanced in after-market trading, recovering from earlier losses amid broader market dynamics and a slight decline in the unemployment rate.

2026. g. 6. aug. 19:16 UTC

OPKO Health Inc. shares are lower today amid notable volatility, with economic data showing initial jobless claims rose slightly ahead of tomorrow's non-farm payrolls report.

2026. g. 5. aug. 23:01 UTC

OPKO Health shares are lower in after-market hours, reflecting broader market weakness amid recent economic data showing weaker-than-expected U.S. job growth.

2026. g. 4. aug. 23:06 UTC

OPKO Health Inc. shares are higher in after-market trading, settling with a cumulative gain following a brief dip at the session's start.

2026. g. 3. aug. 23:01 UTC

OPKO Health Inc shares increased in after-market trading, maintaining a steady rise since Monday's close amid a generally positive market backdrop.

2026. g. 31. jūl. 19:45 UTC

OPKO Health Inc. shares are trading roughly flat today, hovering around the middle of their one-month range and above the 20-day moving average.

2026. g. 30. jūl. 23:11 UTC

OPKO Health Inc. shares are lower in after-market hours, continuing a recent trend amid broader market uncertainty following the Federal Reserve's interest rate decision.

2026. g. 29. jūl. 23:46 UTC

No specific news was identified for OPKO Health Inc. Shares remained roughly flat during after-market hours, trading near unchanged since Wednesday's close.

2026. g. 28. jūl. 23:41 UTC

News

OPKO Health reported a narrowed net loss of $8.4 million and raised revenue guidance, but shares are lower in after-market hours following recent gains.

2026. g. 27. jūl. 23:41 UTC

News

OPKO Health reported second-quarter revenues of $163.5 million, surpassing expectations. The company also raised its full-year sales guidance, boosting shares in after-market trading.

2026. g. 24. jūl. 22:06 UTC

OPKO Health Inc shares are higher in after-market trading, reaching a peak shortly after the market closed. No specific news was identified for this movement.

2026. g. 22. jūl. 18:31 UTC

OPKO Health is declining today, having pulled back from earlier gains amid broader market volatility and rising geopolitical tensions.

2026. g. 21. jūl. 22:56 UTC

No specific news was identified for OPKO Health during after-market hours. The stock remains roughly flat, positioned 12.60% below its 20-day moving average.

2026. g. 20. jūl. 19:51 UTC

OPKO Health Inc shares are higher in Monday's session, reflecting positive trading conditions. Broader market dynamics are supported by strength in Asian markets.

Salīdzinājums

Cenas izmaiņa

OPKO Health Inc Prognoze

Cenas mērķis

By TipRanks

115.83% augšup

Prognoze 12 mēnešiem

Vidējais 3 USD 115.83%

Augstākais 3 USD

Zemākais 3 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi OPKO Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam OPKO Health Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

286 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.